+4.83% gap, then +1.83% from the open. $BKE is higher after Buckle's Q3 beat, with volume at 1.28x normal. One rule from the chart: a move back under the open means the gap is being sold. Education, not advice.
39
+7.48% gap → +8.29% from the open. That's $GAP on a Q3 adjusted EPS beat, with 6.17x volume showing buyers kept pressing. One rule from the chart: the open is the line, and losing it undoes the push. Education, not advice.
56
−0.25% → +15.43%. $INSM gapped flat, then ran on reports Sanofi is weighing a takeover bid, with 5.64x normal volume. One rule from the chart: the open is the level; losing it flags a fade. Education, not advice. #PriceAction
1
184
+3.15% gap → +4.78% from the open. That's $FUTU after better-than-expected Q3 results, on 5.21x normal volume. One rule from the chart: the open is the line; losing it means the gap buyers gave way. Education, not advice. #PriceAction
56
8.24x normal volume. $TTWO is up +2.76% from the open after a +4.27% gap on GTA VI's record-tying review scores. One rule from the chart: the open is the line to watch. Education, not advice. #PriceAction
62
4.90x normal volume. $TGT is +2.17% from the open after a Q3 beat and raised FY26 EPS and revenue guidance. One rule from the chart: a hold above the open keeps the +1.3% gap intact. Education, not advice. #PriceAction
46
5.57x normal volume. $KLAR is +1.56% from the open on top of a +3.63% gap after better-than-expected Q3 sales. One rule from the chart: a break back under the open erases that +1.56%. Education, not advice. #PriceAction
2
173
+248.9% from the open. That's $SLS after the Phase 3 REGAL trial in AML met its primary endpoint, on 67.73x normal volume. One rule from the chart: the open is the line; a drop back to it erases the move. Education, not advice.
1
153
−0.27% → +31.81%. That's $CGON from gap to now after PIVOT-006 hit its primary endpoint, on 5.62x volume. One rule from the chart: the open is the line; a drop back through it undoes the day. Education, not advice. #PriceAction
115
+10.31% gap → +4.4% from the open. $DRTS is higher after its REGAIN glioblastoma trial met safety and feasibility endpoints in all 8 patients. One rule from the chart: the open is the line to watch. Education, not advice. #PriceAction
106
+2.19% gap → +1.58% from the open. $STE: Jefferies upgraded to Buy, target $232 → $305, on 0.92x RVOL. One rule from the chart: the open is the line; a hold above it keeps the gap intact. Education, not advice. #PriceAction
73











